Postępy Dermatologii i Alergologii

Omalizumab and food allergy: does reaction severity improve in adult patients?

  1. Department of Allergy and Immunology, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
Adv Dermatol Allergol
Online publish date: 2026/05/16
View full text

Introduction

In adults, IgE-mediated food allergy is associated with clinically relevant allergic reactions of variable severity. Omalizumab has been shown to reduce food-related reactions in selected populations; however, evidence in adults, particularly those with chronic spontaneous urticaria (CSU), remains limited. Aim: To evaluate whether omalizumab treatment reduces the severity of food-related allergic reactions upon re-exposure in adult patients with chronic spontaneous urticaria and concomitant IgE-mediated food allergy.

Material and methods

Adult patients with CSU receiving omalizumab and a documented history of IgE-mediated food allergy were retrospectively evaluated with a limited prospective component. Reaction severity before and after omalizumab treatment was assessed using the EAACI, Brown, and Ring–Messmer classification systems. Analyses were restricted to patients who were re-exposed to the culprit food after treatment. Baseline clinical and laboratory parameters were compared between responders and non-responders.

Results

Forty adult patients were included (median age: 42 years; 70% were female). Anaphylaxis history was more frequent in patients with chronic spontaneous urticaria and concomitant IgE-mediated food allergy than in CSU patients without food allergy (p = 0.040). Thirty-one patients were re-exposed to the culprit food after initiation of omalizumab treatment. Reaction severity was significantly reduced following treatment across the EAACI, Brown, and Ring–Messmer classification systems (all p < 0.001). Baseline total IgE levels, eosinophil counts, serum tryptase levels, and atopy status were not associated with clinical response. Higher baseline C-reactive protein levels were observed among responders (p = 0.039).

Conclusions

Omalizumab treatment was associated with a consistent reduction in the severity of food-related allergic reactions upon re-exposure in adults with CSU and IgE-mediated food allergy. Clinical improvement occurred largely independently of conventional allergic biomarkers.

Share
without publication fees